OncoArendi - Announcement of the results of procedure No. 1/2022, DUBs

Subject of the contract: Successive supply of sets for the quantitative determination of cytokine and chemokine biomarkers in mouse serum, plasma and cell culture samples using multiplex tests using magnetic deposits using Luminex xMAP technology, delivery 3 (or less) x per week for a period of 9 months from the date of conclusion of the contract.

Having gathered all the information relating to the contract in question and having analysed the completeness of the tenders, the Commission concludes that the most advantageous tender meeting all the requirements of the tender notice was submitted by the company:

Merck Life Science Sp. z o.o.

Szelgowska 30

61-626 Poznan

Total net value of the order: 257 709,60 PLN

The Committee recommends to the Management Board to commission the performance of the contract in question to be performed on the terms of the submitted offer to the above tenderer.

About us

OncoArendi Therapeutics (OncoArendi) is an innovative biotechnology company specializing in the search, development and commercialization of new drugs for the treatment of inflammatory and cancer diseases

Contact:

Phone: [phone]

E: [e-mail]

E: [e-mail]

(C) 2022 Electronic News Publishing, source ENP Newswire